As the world races to find a vaccine for COVID-19, our colleague Dr Cem Gun, an Emergency Medicine Physician at Acıbadem University Atakent Hospital, has bravely volunteered for the country’s first clinical trial. On 9 October, he was administered the first dose of a COVID-19 vaccine developed in China and approved for trial by the Health Institutes of Turkey, at a high-key milestone event.
On why he volunteered for this trial, Dr Cem Gun said, “As a healthcare worker, I fall into the high-risk group for COVID-19 infection. I decided to be vaccinated not only to protect myself but also my patients and loved ones. I made this decision with peace of mind as it is a controlled trial; it is currently in Phase 3, making it a tested and safe vaccine.”
The vaccine will be administered in two doses, and volunteers will be monitored on its effectiveness over a year.
The World Bank has approved US$12 billion in financing to help developing countries buy and distribute COVID-19 vaccines, tests and treatments, aiming to support the vaccination of up to 1 billion people.
Related Stories
IHH Healthcare Deepens Commitment to Reduce Cancer Burden in Malaysia
Learn how our third memorandum of understanding with Ministry of Health Malaysia is expanding access to life-saving, advanced cancer care at 8 of our hospitals.
IHH Healthcare Bags Five Wins at the 15th Asian Excellence Awards
Celebrating our leadership, sustainability, and investor relations excellence on the regional stage.
Fortis CEO Shares Vision for a Healthier India on NDTV
Here is a look at how Fortis is contributing to India’s healthcare transformation.
IHH Singapore Hits New Digital and Imaging Milestones
Across Singapore, IHH Healthcare is transforming care delivery through data, technology and frontline innovation.
Parkway Radiology Deploys Annalise.ai Chest X-ray AI Solution
Parkway Radiology has implemented the Annalise.ai Enterprise CXR solution across all its radiology clinics and hospital departments in Singapore. This represents the first network-wide deployment of the chest X-ray AI technology in the country.
Fortis Enhances Diagnostic and Paediatric Care at S L Raheja Hospital, Mumbai
S L Raheja Hospital, a Fortis Associate, has significantly expanded its diagnostic and paediatric capabilities with the launch of AI-enabled Digital Positron Emission Tomography–Computed Tomography (PET-CT), 3 Tesla Magnetic Resonance Imaging (MRI), and upgraded Neonatal Intensive Care Unit (NICU) and Paediatric Intensive Care Unit (PICU) services.
